These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 27529526)

  • 21. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.
    Stahmeyer JT; Rossol S; Bert F; Böker KH; Bruch HR; Eisenbach C; Link R; John C; Mauss S; Heyne R; Schott E; Pfeiffer-Vornkahl H; Hüppe D; Krauth C
    PLoS One; 2016; 11(7):e0159976. PubMed ID: 27467772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
    Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M
    Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
    Dintsios CM; Haverkamp A; Wiegand J; Gerlach T; Wedemeyer H; Pape G; Manns MP; Krauth C
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):278-88. PubMed ID: 19550347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.
    San Miguel R; Gimeno-Ballester V; Blázquez A; Mar J
    Gut; 2015 Aug; 64(8):1277-88. PubMed ID: 25311032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
    PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.
    Gimeno-Ballester V; Mar J; O'Leary A; Adams R; San Miguel R
    Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):85-93. PubMed ID: 27500437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
    Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
    Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
    Cure S; Guerra I; Cammà C; Craxì A; Carosi G
    J Med Econ; 2015; 18(9):678-90. PubMed ID: 25891129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
    Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
    Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
    Petta S; Cabibbo G; Enea M; Macaluso FS; Plaia A; Bruno R; Gasbarrini A; Craxì A; Cammà C;
    Hepatology; 2014 May; 59(5):1692-705. PubMed ID: 24691835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
    Lidgren M; Hollander A; Weiland O; Jönsson B
    Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy.
    Melendez-Mena D; Mendoza-Torres MA; Sedeño-Monge V; García Y García VH; Rivera-García E; Sánchez-Reza L; Baxin Domínguez MDC; Guzmán-Flores B; Martinez-Laguna Y; Coronel Espinoza JM; Galindo-Santiago I; Flores-Alonso JC; Vallejo-Ruiz V; Cortes-Hernandez P; Reyes-Leyva J; Sosa-Jurado F; Santos-López G
    PeerJ; 2021; 9():e12051. PubMed ID: 34616602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
    Sethi N; Tapper EB; Vong A; Sethi S; Rourke M; Afdhal NH
    J Viral Hepat; 2015 Dec; 22(12):974-6. PubMed ID: 26010946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
    Younossi ZM; Elsheikh E; Stepanova M; Gerber L; Nader F; Stamm LM; Brainard DM; McHutchinson JG
    J Viral Hepat; 2015 Dec; 22(12):977-82. PubMed ID: 26280786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
    Shiffman ML; James AM; Long AG; Alexander PC
    Am J Gastroenterol; 2015 Aug; 110(8):1179-85. PubMed ID: 26215530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.